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and Schizophrenia
Awadalla et al., page 316
De novo mutations (DNMs) may contribute to the devel-
opment of complex disease and may explain some of
the missing heritability that has not been identified via
linkage analyses and association studies. Current indirect
estimates of the neutral mutation rate in humans suggest
that at least a couple DNMs will occur in each individual,
and it is predicted that, if such mutations do affect disease
susceptibility, they should occur at functional sites more
often in patients with the disease than in those who do
not have the disease. But are current estimates of the
neutral mutation rate accurate, and is there yet enough
evidence that DNMs really do play a role in disease risk?
Awadalla et al. seek to evaluate these questions by rese-
quencing synaptic genes in patients with autism spectrum
disorder (ASD) or schizophrenia (SCZ). Variants that are
identified are then determined to be de novo by evaluation
of parent samples. The authors’ direct estimates of the
neutral mutation rate are similar to those reported previ-
ously. They then demonstrate that, in the patient cohorts,
DNMs with functional effects are enriched over those that
are predicted to affect nonfunctional sites. With the data at
hand, Awadalla et al. are also able to compare the sites
affected by DNMs with those that segregate in their patient
families to show that segregating variants aren’t as likely to
affect functional sites. These analyses suggest that DNMs
in synaptic genes are a risk factor for the development of
ASD and SCZ.Boost a Car or BOOST Your Analysis
Wan et al., page 325
Looking for gene-gene interactions that have an effect on
disease is a bit more complicated than analyzing single
markers for association with disease risk. Similar to playing
a game of Memory, in which you get to progress through
the game only if you flip over two cards that match each
other, significant signals are observed only when two
markers are assessed at the same time. This means that if
a systematic analysis is to be done, each marker has to be
tested alongside every other marker individually; with
genome-wide SNP data, that works out to be a whole lot
of tests. Some methodologies limit this number of tests1Science Editor, AJHG; 2Deputy Editor, AJHG
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contributing factors, but making such decisions ahead
of time can mean discarding data that may be important.
A central goal of some algorithms, then, is to look for an
association between all pairs of markers and disease status
without exhausting computational resources. In this issue,
Wan and colleagues describe their answer to this problem:
BOOST. The authors present the results of simulations to
demonstrate the advantages of using BOOST in the study
of gene-gene interactions. They then use BOOST to eval-
uate pairs of markers in the Wellcome Trust Case Control
Consortium data from seven common diseases and find
that BOOST is able to handle these data in significantly
less time than is possible for other current methodologies.
The differences that they report in the interaction patterns
of markers in association with type 1 diabetes versus those
in association with rheumatoid arthritis may reveal insight
into the etiologies of the diseases.Mutability of Y Chromosome Microsatellites
Ballantyne et al., page 341
Genetic analysis of the Y chromosome is an integral piece
of population studies, forensic evaluations, and genealog-
ical surveys. By looking at the nonrecombining region of
the Y chromosome (NRY), researchers are able to follow
the male lineage through generations and make estima-
tions about the evolution of a population and the genetic
distance of male relationships. All of these applications
require an accurate assessment of the mutation rate of
markers in the NRY. With evidence demonstrating that
these rates are highly variable from one marker to the
next, empirical determination of the mutation rate for
each individual marker may be the best way to incorporate
reliable data into calculations. In this issue, Ballantyne
et al. closely investigate markers in the NRY and establish
mutation rate values for each marker. They observe a
wide range of values and evaluate how characteristics of
the markers correlate with their mutability. In addition,
the authors break the markers into groups on the basis of
their mutability. Markers with low mutation rates can be
useful in distinguishing distantly related male lineages
from each other, but they will not be so useful in forensic
applications that require the ability to differentiate close
male relatives from one another. Such forensic analysis
would benefit from the evaluation of markers with knownGenetics. All rights reserved.
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higher mutation rates. In this regard, the authors’ data not
only provide mutation rate values for integration into
better assessments of population history and evolution,
but also establish which markers are best suited for
particular applications.TBC1D24 Mutations in Idiopathic Epilepsy
and Intellectual Disability
Falace et al., page 365; Corbett et al., page 371
Idiopathic epilepsy (IE) is the name given to a seizure
condition having no apparent cause. Seizures result from
abnormal neuronal activity in the brain. The recurrent
seizures in IE are present in the absence of detectable brain
lesions or metabolic abnormalities and are the primary
feature of IE. These seizures can impair consciousness
and distort the electrical activity of the brain. Genetics
are thought to play a prominent role in IE despite the
fact than few mutations are currently associated with this
condition. In this issue, Falace and colleagues and Corbett
and colleagues both identify missense mutations in
TBC1D24 in patients with IE. Both groups combine
different techniques to identify the mutations. Falace
and colleagues use SNP genotyping and haplotype analysis
followed by candidate gene sequencing to identify
compound heterozygous TBC1D24 mutations in a large
Italian family. Corbett and colleagues perform linkage
analysis and then utilize next-generation sequencing to
sequence the entire linked region in a large Israeli family
with IE and intellectual disability. After sorting through
the identified variants, Corbett et al. confirm a TBC1D24
homozygous missense mutation as segregating with
disease in this family. Both groups of researchers find
TBC1D24 to be expressed in the brain. To define the
function of TBC1D24, a largely uncharacterized protein,
both groups perform in vitro analyses. They conclude
that TBC1D24 has a role in neuronal outgrowth. Together,312 The American Journal of Human Genetics 87, 311–312, Septembthe localization of TBC1D24 expression and the function
of TBC1D24 support the role of the identified pathogenic
TBC1D24 mutations in IE.Mutations in FAM161A Cause Autosomal-Recessive
Retinitis Pigmentosa
Langmann et al., page 376; Bandah-Rozenfeld et al.,
page 382
Retinitis pigmentosa (RP) refers to a group of hereditary eye
diseases. This heterogeneous condition is characterized by
the accumulation of pigment-like deposits in the retina.
Although the details of pathogenesis can vary greatly, all
RP patients suffer from progressive retinal degeneration,
often leading to complete blindness. Numerous genetic
mutations in several different genes have been associated
with different forms of RP. However, many cases of RP
have no identified genetic cause. Here, two different
groups of researchers identify mutations in a new gene
associated with autosomal-recessive RP (arRP). Langmann
and colleagues use a combination of two techniques to
identify FAM161A mutations in an Indian arRP family.
They utilize next-generation exon capture and sequencing
of a region previously linked with RP in this family and
simultaneously analyze chromatin immunoprecipitation
data of murine retinal transcription factor target genes.
FAM161A is found to be the top candidate in both assays.
Nonsense mutations in this gene are then found in the
original family and in additional arRP families. Bandah-
Rozenfeld and colleagues take another approach. They
use a combination of homozygosity mapping and candi-
date gene sequencing. Of the 12 candidate genes, only
FAM161A is found to contain segregating pathogenic
variants. In total, Bandah-Rozenfeld and colleagues iden-
tify three different mutations in 20 arRP families. Together,
these data leave little doubt that FAM161A mutations
lead to arRP.er 10, 2010
